GlassScriptPhysician profile
Michael Dominisse
NPI 1962914580
$6,798.52
in general payments reported to CMS, 2019-2025
25 companies · $2,070 in 2025
The $2,070 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $826 · 2022: $1,152 · 2023: $1,166 · 2024: $1,584 · 2025: $2,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,614 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,613.97 |
| Education | $206.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,200.32 | 2021-2025 | |
| Abbvie INC. | $762.00 | 2021-2025 | |
| Genzyme Corporation | $717.33 | 2022-2025 | |
| Janssen Biotech, INC. | $674.36 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $547.54 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $406.52 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $369.97 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $343.28 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Lilly USA, LLC | $191.82 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Almirall LLC | $183.12 | 2021-2025 | Klisyri, Seysara |
| Biofrontera INC. | $161.13 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $149.99 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $146.83 | 2021-2025 | Anzupgo, Adbry |
| Janssen Scientific Affairs, LLC | $123.76 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $120.32 | 2021-2025 | Jublia, Cabtreo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $100.14 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Incyte Corporation | $96.13 | 2022-2025 | Opzelura |
| Ucb, INC. | $90.77 | 2021-2024 | Bimzelx |
| Pfizer INC. | $84.10 | 2021-2024 | |
| Dermavant Sciences, INC. | $82.93 | 2022-2023 | Vtama |
| Epi Health, LLC | $53.43 | 2021-2022 | |
| Medimetriks Pharmaceuticals, INC. | $36.52 | 2025 | Neo-Synalar, Clindacin Etz |
| Convatec INC. | $36.02 | 2025 | |
| Dermira, INC. | $20.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dominisse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.